Eli Lilly and Company (LLY)

NYSE: LLY · Real-Time Price · USD
765.68
-0.16 (-0.02%)
At close: Jun 5, 2025, 4:00 PM
770.80
+5.12 (0.67%)
Pre-market: Jun 6, 2025, 8:51 AM EDT
-0.02%
Market Cap 687.38B
Revenue (ttm) 49.00B
Net Income (ttm) 11.11B
Shares Out 897.74M
EPS (ttm) 12.29
PE Ratio 62.30
Forward PE 30.68
Dividend $6.00 (0.78%)
Ex-Dividend Date May 16, 2025
Volume 3,638,629
Open 769.50
Previous Close 765.84
Day's Range 753.05 - 770.00
52-Week Range 677.09 - 972.53
Beta 0.49
Analysts Strong Buy
Price Target 1,014.22 (+32.46%)
Earnings Date May 1, 2025

About LLY

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]

Sector Healthcare
Founded 1876
Employees 47,000
Stock Exchange NYSE
Ticker Symbol LLY
Full Company Profile

Financial Performance

In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial Statements

Analyst Forecast

According to 18 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price forecast is $1,014.22, which is an increase of 32.46% from the latest price.

Price Target
$1,014.22
(32.46% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Rare Outflow Signals Hit Eli Lilly Shares

“Buy low, sell high” is a common investing mantra. It's easy to understand, but often hard to execute because emotion gets in the way.

2 hours ago - FXEmpire

Lilly's Jake Van Naarden: Lilly's success with GLP-1's allows us to reinvest in oncology

CNBC's Angelica Peebles sits down with Lilly's Head of Oncology, Jake Van Naarden, to discuss what's next in Lilly's oncology pipeline and what Lilly is changing about its clinical trials to make them...

23 hours ago - CNBC Television

Welldoc Works with Lilly to Launch a New Personalized Health & Medicine Platform for Those Prescribed Lilly's Incretin Therapies

COLUMBIA, Md.--(BUSINESS WIRE)--Welldoc®, a leader in AI-powered digital health innovation, today announced it will power the newly launched Lilly Health™ Personalized Health & Medicine Platform* (Lil...

1 day ago - Business Wire

Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins

Partnership focused on development of long-acting therapies based on Camurus' FluidCrystal® technology and Eli Lilly's proprietary drug compounds Camurus eligible to receive up to $870 million in pote...

2 days ago - PRNewsWire

Top 50 High-Quality Dividend Stocks For June 2025

I track 50 high-quality dividend growth stocks to identify opportune investments, updating valuation ratings daily to focus on attractive opportunities. In this turbulent year, my investable universe ...

2 days ago - Seeking Alpha

LLY Stock Too Cheap At $750?

Question: Why would you pay 81 times earnings for AbbVie stock when you can buy LLY for a similar valuation of 76 times earnings? You wouldn't, especially when you consider three simple facts:

2 days ago - Forbes

Biotech Bull Case, ABVX International Interest, JNJ & LLY Options Trades

"You cannot not believe in science," says Tsvetta Kaleynska. She sees biotech companies outperforming in 2025 despite a slow start to the year.

Other symbols: JNJABVX
3 days ago - Schwab Network

Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference

INDIANAPOLIS , June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 46th Annual Global Health Care Conference on June 10, 2025. Lucas Montarce, Lilly exe...

3 days ago - PRNewsWire

Targeting The NaV1.8 Pathway In Pain Management: Eli Lilly And Vertex Lead The Way

Both Vertex and Eli Lilly are entering the non-opioid pain management market, targeting the promising $20B+ opportunity. Vertex's Journavx, targeting NaV1.8, is FDA-approved and shows opioid-level pai...

4 days ago - Seeking Alpha

Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting

INDIANAPOLIS , June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its folate receptor alpha (FRα) antibody-drug conjugate (ADC) (LY4170156) de...

4 days ago - PRNewsWire

Eli Lilly Rises 1.5% After Key Trading Signal

TradePulse Alert Confirms Early Up Move in LLY

4 days ago - Benzinga

5 Alpha Generating Monsters

Any stock can generate alpha, but doing it consistently is rare. These 5 stocks have delivered alpha for 4 out of the last 5 years. Valuation is important, so I screen for it and eliminate overpriced ...

Other symbols: APOCOKEENVAFICO
6 days ago - Seeking Alpha

Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions

INDIANAPOLIS , May 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatr...

7 days ago - PRNewsWire

Breaking The Pain Barrier: Lilly's Acquisition Of SiteOne Aims For Opioid Alternatives

Eli Lilly And Co LLY on Tuesday agreed to acquire SiteOne Therapeutics, Inc., a private biotechnology company developing small-molecule inhibitors of sodium channels to treat pain and other neuronal h...

9 days ago - Benzinga

Eli Lilly to acquire privately held SiteOne

Eli Lilly will acquire privately held SiteOne Therapeutics, the companies said on Tuesday, giving the drugmaker access to an experimental non-opioid pain drug.

9 days ago - Reuters

Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics

Transaction will augment Lilly's efforts to advance non-opioid medicines for pain management INDIANAPOLIS , May 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc...

9 days ago - PRNewsWire

Weight-loss drugs like Ozempic and Wegovy continue to be in high demand—and expensive. Are prices likely to come down soon?

The supply of GLP-1 drugs has been increasing, but they're still expensive for most patients. Here are answers to some questions consumers have.

Other symbols: NVO
9 days ago - WSJ

Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

INDIANAPOLIS , May 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of imlunestrant, an investigational oral selective estrogen receptor degrader (SERD...

14 days ago - PRNewsWire

Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs

Cigna's Evernorth unit said a new coverage deal with Eli Lilly and Novo Nordisk will bring lower copays for insured patients The company hopes the new discount, which caps monthly out-of-pocket costs ...

Other symbols: CINVO
15 days ago - CNBC

Lilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease

The authorization in Australia is for adult patients who are Apolipoprotein E- ε 4 heterozygotes or non-carriers INDIANAPOLIS , May 21, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced...

15 days ago - PRNewsWire

Eli Lilly: Obesity Drug Development To Go Beyond That Of Zepbound

The company delivered 45% revenue growth in Q1 2025, driven by ZEPBOUND and MOUNJARO's strong performance in the obesity and diabetes markets. ZEPBOUND outperformed Novo Nordisk's WEGOVY in terms of w...

20 days ago - Seeking Alpha

Eli Lilly pulls ahead of Novo in obesity drug gold rush as new players crowd in

The global weight-loss drug market, once dominated by Novo Nordisk, is undergoing a dramatic transformation. On Friday, the Danish pharmaceutical giant announced it would replace its long-serving chie...

20 days ago - Invezz

3 Stocks That Will Profit From Trump's Drug Price Cut

On May 12, President Donald Trump followed through on a campaign promise by signing an Executive Order (EO) mandating that pharmaceutical companies lower their prescription drug prices in the US to th...

Other symbols: ABBVNVO
20 days ago - Benzinga

Eli Lilly and Company (LLY) BofA Securities 2025 Health Care Conference Call Transcript

Eli Lilly and Company (NYSE:LLY) BofA Securities 2025 Health Care Conference Call May 15, 2025 11:40 AM ET Company Participants Lucas Montarce - CFO Mike Czapar - SVP, IR Conference Call Participants...

21 days ago - Seeking Alpha

Pfizer, Eli Lilly, and Other Pharma Stocks Fall. Questions Remain About Trump's Executive Order.

There are significant questions on how the order can be implemented, and if companies can raise prices on already approved drugs, analysts say.

Other symbols: PFEABBVJNJ
23 days ago - Barrons